Stem Cell Therapy for Premature Ovarian Failure: What a Phase I Trial Found

A Phase I trial tested stem cells in 35 women with premature ovarian failure, reporting hormonal improvements and return of menstruation in some patients.

Stem Cell Therapy for Premature Ovarian Failure: What a Phase I Trial Found

Could stem cells offer a new path forward for women living with premature ovarian failure? For many patients, current treatment options address symptoms but fall short of restoring ovarian function or fertility. A recently completed Phase I clinical trial explored whether human amniotic epithelial cells (hAECs) — a type of stem cells sourced from placental tissue — could produce meaningful changes in women with this condition.

The trial enrolled 35 patients and reported improvements across hormone levels, menstrual activity, ovarian morphology, and quality of life over a five-month follow-up period. While the findings are early-stage, they have added to a growing body of research examining stem cells as a potential therapeutic tool in reproductive medicine.

What Is Premature Ovarian Failure?

Premature ovarian failure (POF) — also referred to as primary ovarian insufficiency (POI) — is a condition in which the ovaries stop functioning normally before a woman reaches the age of 40. Unlike natural menopause, POF can occur as early as the teenage years and is often unexpected, leaving patients without adequate preparation or clear treatment options.

The condition is estimated to affect around 3.5% of women globally. It can be caused by autoimmune disorders, genetic factors such as Turner syndrome, environmental exposures, or as a side effect of medical treatments like chemotherapy or radiation. In many cases, however, no identifiable cause is found.

The ovaries serve a dual role: they regulate the menstrual cycle and produce the sex hormones — primarily estrogen and progesterone — that influence a wide range of bodily functions. When ovarian function declines prematurely, the effects are felt well beyond reproductive health.

Symptoms and Health Consequences

The most recognizable symptom of POF is irregular or absent menstruation, but the broader hormonal impact creates a cluster of symptoms that can significantly affect daily life. These include hot flashes and night sweats, sleep disturbances, memory difficulties, irritability, vaginal dryness, reduced libido, and painful intercourse. Over the longer term, low estrogen levels increase the risk of osteoporosis and cardiovascular disease.

Fertility is also affected, with patients experiencing either primary or secondary infertility depending on when the condition develops. For women who were hoping to conceive, a POF diagnosis can be particularly distressing.

How Is It Diagnosed?

Diagnosis is based on three criteria in women under 40: at least four to six months of absent or infrequent periods; FSH levels above 40 IU/L confirmed on two separate blood tests taken more than four weeks apart; and reduced estrogen levels accompanied by menopausal-type symptoms.

Current Treatment and Its Limitations

The standard approach to managing premature ovarian failure is hormone replacement therapy (HRT), which helps alleviate estrogen-deficiency symptoms and offers some protection against bone loss and cardiovascular risk. For many patients, HRT provides meaningful relief and remains an important part of care.

However, HRT does not address the underlying depletion of the ovarian follicle reserve, and it does not restore fertility. Women who wish to conceive after a POF diagnosis typically face significant challenges, and assisted reproduction outcomes are generally poor due to the absence of viable eggs. This unmet clinical need has prompted researchers to investigate whether regenerative approaches — particularly those involving stem cells — could go beyond symptom management to support actual tissue repair and functional recovery.

Why Human Amniotic Epithelial Stem Cells?

Human amniotic epithelial cells (hAECs) are derived from the innermost layer of the placenta, a tissue that is routinely discarded after delivery. This makes them an ethically accessible source of stem cells, free from the controversies surrounding embryonic stem cell research.

hAECs possess properties that make them scientifically interesting for regenerative applications. They exhibit pluripotent-like characteristics — meaning they have the capacity to differentiate into multiple cell types — and they carry low immunogenicity, reducing the risk of immune rejection when used in allogeneic (donor-to-patient) therapies. Preclinical studies have suggested that hAECs may support tissue repair and create a more favorable cellular environment in damaged or depleted organs, including the ovaries.

These characteristics have made hAECs a focus of clinical research in several therapeutic areas, with reproductive medicine being one of the more active fields of investigation.

The Phase I Clinical Trial

Trial Design and Patient Profile

The trial, registered on ClinicalTrials.gov under identifier NCT02912104, was a Phase I study designed to evaluate the safety and preliminary effects of hAEC infusion in patients with premature ovarian failure. It was conducted in China under applicable ethics review and regulatory oversight for early-phase cell therapy research.

Thirty-five patients were enrolled and evaluated. Their mean age was 34.57 years, ranging from 18 to 45, and the average duration of amenorrhea before entering the trial was 4.71 years — indicating a patient population with well-established ovarian insufficiency. The majority (91.43%) had previously undergone hormone replacement therapy, either continuously or intermittently, while a small proportion (8.57%) had not received HRT for at least one year prior to enrollment.

How the Treatment Was Administered

All patients received a single infusion of human amniotic epithelial cells delivered directly to the ovarian tissue via the ovarian artery. The procedure used an interventional radiology approach: access was gained through the femoral artery, a catheter was guided to the uterine artery, and superselective cannulation was performed on the ovarian branch. The stem cells were then slowly infused through a microcatheter to ensure targeted delivery.

The average procedure time was 53.4 minutes, and nearly 95% of patients were discharged within 24 hours. Follow-up assessments took place at one month, three months, and five months after treatment.

What the Trial Found

Return of Menstruation

One of the most clinically significant findings was the return of spontaneous menstrual bleeding in a meaningful proportion of patients. Compared with the five months before treatment, 37.14% of patients (13 of 35) experienced at least one spontaneous menstrual episode after receiving hAEC therapy. Among these, 20% (7 of 35) reported more than one episode of regular menstrual activity — a notable outcome in a population where amenorrhea had persisted for an average of nearly five years.

Hormonal Improvements

Patients showed measurable changes in two key hormonal markers associated with ovarian function.

FSH levels — which are elevated in POF as the body attempts to stimulate non-responsive ovaries — declined progressively following treatment, reaching statistical significance at the five-month follow-up. This downward trend suggests an improvement in the hypothalamic-pituitary-ovarian feedback loop.

Estradiol (E2) levels, which are typically low in POF, increased significantly at both the one-month and five-month timepoints. Rising E2 is associated with active follicular development and carries direct implications for symptom relief, bone protection, and cardiovascular health.

Structural Changes in the Uterus and Ovaries

Endometrial thickness — a key marker of uterine receptivity and estrogenic activity — increased significantly at one and five months post-treatment. Additionally, a statistically significant enlargement of the left ovary was observed one month after the procedure (p = 0.041), potentially reflecting improved follicular activity or enhanced tissue perfusion.

Quality of Life

Menopausal symptom burden was assessed using the validated Menopause-Specific Quality of Life (MENQOL) questionnaire, which covers vasomotor, physical, psychosocial, and sexual domains. Scores improved progressively across all four areas throughout the follow-up period, with the most sustained gains observed at five months. Physical symptom scores and sexual functioning scores both showed statistically significant improvements compared with baseline.

Oocyte Retrieval After Prior IVF Failure

Among the 35 patients, six had previously undergone unsuccessful IVF-ET (in vitro fertilization and embryo transfer) cycles before entering the trial. Following hAEC treatment, all six were able to proceed with oocyte retrieval — something that had not been possible in their prior treatment attempts. One patient retrieved two viable eggs approximately two months after the stem cell procedure, without any accompanying hormonal stimulation, yielding two frozen embryos. While this represents a single case, it is a finding that warrants attention in the context of future fertility-focused research.

Safety

The safety profile observed in this trial was consistent with what would be expected from a minimally invasive interventional procedure. Reported adverse events included localized hematoma at the femoral access site, transient fever, and mild pelvic discomfort. The majority resolved without specific treatment. No serious adverse events were recorded during the observation period.

Context and Limitations

This trial was conducted in China and registered through an internationally recognized clinical trial registry. Its findings are relevant to the broader global conversation around stem cell applications in reproductive medicine, a field that is actively being explored by research institutions across North America, Europe, and Asia.

That said, it is important to view these results within their appropriate limitations. As a Phase I study, the trial was primarily designed to evaluate safety and feasibility — not to definitively prove efficacy. There was no placebo or control group, the sample size was relatively small, and the follow-up period extended only to five months. These factors limit the conclusions that can be drawn.

It is also noted that patients with a severely depleted follicle reserve may not respond sufficiently to a single treatment cycle. Some patients may require repeated infusions to sustain or build upon the initial response, and AMH levels — a marker of ovarian reserve — may not reflect significant changes after one session alone.

Larger randomized controlled trials with longer follow-up durations are needed before stem cell therapy for premature ovarian failure can be considered for clinical application outside of a research setting.

Conclusion

This Phase I trial provides early clinical evidence that intra-arterial infusion of human amniotic epithelial stem cells is a feasible and well-tolerated approach in women with premature ovarian failure. Across a five-month follow-up, patients showed measurable improvements in hormone levels, menstrual activity, uterine and ovarian morphology, and self-reported quality of life. The successful oocyte retrieval in patients with prior IVF failure adds a dimension of fertility-related interest to these findings.

The results are preliminary and should not be interpreted as evidence of an established treatment. However, they do contribute meaningfully to the scientific case for continued investigation of stem cells as a therapeutic approach in reproductive medicine — and for the women living with premature ovarian failure, that continued research represents a genuine source of clinical hope.